Globeflex Capital L P Invests $1.08 Million in Cerus Corporation $CERS

Posted by George Bondi on Jun 5th, 2026

Globeflex Capital L P acquired a new position in shares of Cerus Corporation (NASDAQ:CERS – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 522,099 shares of the biotechnology company’s stock, valued at approximately $1,076,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in Cerus by 291.6% in the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after buying an additional 1,064,133 shares during the last quarter. UBS Group AG raised its stake in shares of Cerus by 227.1% during the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company’s stock worth $2,354,000 after purchasing an additional 793,244 shares during the last quarter. Millennium Management LLC grew its holdings in Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after acquiring an additional 519,301 shares during the period. Qube Research & Technologies Ltd grew its holdings in Cerus by 156.5% during the second quarter. Qube Research & Technologies Ltd now owns 749,564 shares of the biotechnology company’s stock worth $1,057,000 after acquiring an additional 457,347 shares during the period. Finally, Algert Global LLC grew its holdings in Cerus by 451.3% during the third quarter. Algert Global LLC now owns 509,636 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 417,200 shares during the period. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Richard J. Benjamin sold 101,740 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $1.66, for a total transaction of $168,888.40. Following the sale, the insider directly owned 777,361 shares in the company, valued at approximately $1,290,419.26. This trade represents a 11.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Mariner Greenman sold 447,757 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $743,276.62. Following the sale, the chief executive officer owned 4,998,493 shares in the company, valued at approximately $8,297,498.38. The trade was a 8.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 916,001 shares of company stock valued at $1,574,123. Corporate insiders own 5.60% of the company’s stock.

Cerus Stock Performance

NASDAQ CERS opened at $2.79 on Friday. The business’s 50-day moving average price is $2.26 and its 200 day moving average price is $2.16. The company has a market capitalization of $559.03 million, a PE ratio of -55.80 and a beta of 1.77. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47. Cerus Corporation has a twelve month low of $1.15 and a twelve month high of $3.15.

Cerus (NASDAQ:CERS – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $59.89 million for the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. On average, research analysts predict that Cerus Corporation will post -0.02 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Friday, May 1st. Zacks Research raised shares of Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Check Out Our Latest Analysis on Cerus

About Cerus

(Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.